EHA 2023 | IMPROVE study update: safety and efficacy of venetoclax retreatment in R/R CLL

This EHA meeting, we are presenting the results of the retreatment with venetoclax within the IMPROVE study. So the original study was administering treatment with venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, and was MRD-guided, so those who achieved undetectable MRD could stop treatment and proceed with follow-up only. During follow-up, about 17 patients progressed and 13 were eligible for retreatment with venetoclax. So, it’s quite early timepoints after a treatment restart, but we were able to achieve an overall response rate of around 80% and treatment with venetoclax was very well tolerated, without any sign of tumor lysis syndrome or any relevant adverse events, besides the expected neutropenia. Of course, we aim to collect a longer follow-up in order to understand how durable is the response we achieve with venetoclax retreatment. And, as long as the number of patients treated with venetoclax increases, we will be also able to understand if any specific disease features are associated with a higher chance of response.